Successful application of a direct detection slide-based sequential phenotype/genotype assay using archived bone marrow smears and paraffin embedded tissue sections

Journal of Molecular Diagnostics

Volumn 9, Issue 5, 2007, Pages 589-597

  Bedell, Victoria ^a   Forman, Stephen J ^a   Gaal, Karl ^a   Pullarkat, Vinod ^a   Weiss, Lawrence M ^a   Slovak, Marilyn L ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARAFFIN;

ARTICLE; BONE MARROW; CELL STRUCTURE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENOTYPE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MOLECULAR CLONING; PHENOTYPE; RELIABILITY; REPRODUCIBILITY; RISK ASSESSMENT; SMEAR; TARGET CELL; TISSUE SECTION;

EID: 36349035990     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.2353/jmoldx.2007.070050     Document Type: Article

References (36)

1. Paternoster SF, Brockman SR, McClure RF, Remstein ED, Kurtin PJ, Dewald GW: A new method to extract nuclei from paraffin-embedded tissue to study lymphomas using interphase fluorescence in situ hybridization. Am J Pathol 2002, 160:1967-1972
2. Shimoni A, Nagler A, Kaplinsky C, Reichart M, Avigdor A, Hardan I, Yeshuran M, Daniely M, Zilbertstein Y, Amariglio N, Brok-Simoni F, Rechavi G, Trakhtenbrot L: Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using the BioView (Duet™) combined morphological and cytogenetic analysis. Leukemia 2002, 16:1413-1418
3. Weber-Matthiesen K, Winkemann M, Muller-Hermelink A, Schlegelberger B, Grote W: Simultaneous fluorescence immunophenotyping and interphase cytogenetics: a contribution to the characterization of tumor cells. J Histochem Cytochem 1992, 40:171-175
4. Zhang Y, Siebert R, Matthiesen P, Harder S, Theile M, Scherneck S, Schlegelberger B: Feasibility of simultaneous fluorescence in situ hybridization study for the detection of estrogen receptor expression and deletions of the estrogen receptor gene in breast carcinoma cell lines. Virchows Arch 2000, 436:271-275
5. Martín-Subero JI, Chudoba I, Harder L, Gesk S, Grote W, Novo FJ, Calasanz MJ, Siebert RJ: Multicolor-FICTION: expanding the possibilities of combined morphologic, immunophenotypic, and genetic single cell analysis. Am J Pathol 2002, 161:413-420
6. Hardan I, Rothman R, Gelibter A, Cohen N, Shimoni A, Sokolovsky M, Reichart M, Isohev G, Amariglio N, Rehcavi G, Nagler A, Trakhtenbrot I: Determination of chromosome 13 status in bone marrow cells of patients with multiple myeloma using combined morphologic and fluorescence in situ hybridization analysis. Exp Hematol 2004, 32:254-260
7. Slovak ML, Bedell V, Pagel K, Chang KL, Smith D, Somlo G: Targeting plasma cells improves detection of cytogenetics aberrations in multiple myeloma: phenotype/ genotype fluorescence in situ hybridization. Cancer Genet Cytogenet 2005, 158:99-109
8. Pullarkat V, Bedell V, Kim Y, Bhatia R, Nakamura R, Forman S, Sun J, Senitzer D, Slovak ML: Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived form the leukemic clone. Leuk Res 2007, 31:261-265
9. Tubbs RR, Swain E, Pettay JD, Hicks DG: An approach to the validation of novel molecular markers of breast cancer via TMA-based FISH scanning. J Mol Histol 2007, 38:141-150
10. Richmond J, Bryant R, Trotman W, Beatty B, Lunde J: FISH detection of t(14;18) in follicular lymphoma on Papanicolaou stained archival cytology slides. Cancer (Cancer Cytopathol) 2006, 108:198-204
11. Wiktor AE, Van Dyke DL, Stupca PJ, Ketterling RJ, Thorland EC, Shearer BM, Fink SR, Stockero KJ, Majorowicz JR, DeWald GW: Preclinical validation of fluorescence in situ hybridization assays for clinical practice. Genet Med 2006, 8:16-23
12. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil K, Mohamed A, Paietta E, Willman C, Head DR, Rowe JM, Forman SJ, Appelbaum FR: Karyotypic analysis predicts outcome of pre-remission and postremission therapy in adult acute myeloid leukemia (AML): a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000, 96:4075-4083
13. Moorman AV, Harrison CJ, Buck GA, Richards SM, Seeker-Walker LM, Martineau M, Vance GH, Cherry AM, Higgins RR, Fielding AK, Foroni L, Paietta E, Tallman MS, Litzow MR, Wiernick PH, Rowe JM, Goldstone AH, Dewald GW: Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII / Eastern Cooperative Oncology Group (ECOG) 2993 Trial. Blood 2007, 109:3189-3197
14. Fröhling S, Sclenk RF, Kayser S, Morhardt M, Benner A, Dohner K, Donner H: Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood 2006, 108:3280-3288
15. Vitale A, Guarini A, Chiaretti S, Foa R: The changing scene of adult acute lymphoblastic leukemia. Curr Opin Oncol 2006, 18:652-659
16. Schultz KR, Pullen DJ, Sather HN, Shuster JJ, Devidas M, Borowitz MJ, Carroll AJ, Heerema NA, Rubnitz JE, Loh ML, Raetz EA, Winick NJ, Hunger SP, Carroll WL, Gaynon PS, Camitta BM: Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood 2007, 109:926-935
17. Barlogie B, Zangari M, Bolejack V, Hollmig K, Anaissie E, van Rhee F, Pineda-Roman M, Mohiuddin A, Crowley J, Tricot G: Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myeloma. Clin Lymphoma Myeloma 2006, 6:469-474
18. Jagannath S, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Cowan JM, Anderson KC: Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007, 21:151-157
19. Gutiérrez NC, Castellanos MV, Martin ML, Mateos MV, Hernandez JM, Fernandez M, Carrera D, Rosinol L, Ribera JM, Ojanguren JM, Palomera L, Gardella S, Escoda L, Hernandez-Boluda JC, Bello JL, de la Rubia J, Lahuerta JJ, San Miguel JF: Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 2007, 21:143-153
20. Sagaster V, Ludwig H, Kaufmann H, Odelga V, Zojer N, Ackermann J, Kuenburg E, Wieser R, Zielinski C, Drach J: Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia 2007, 21:164-168
21. Wu KL, Beverloo B, Lokhorst HM, Segeren CM, van der Holt B, Steijaert MM, Westveer PH, Poddighe PJ, Verhoef GE, Sonneveld P: Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Br J Haematol 2007, 136:615-623
22. Dewald GW, Therneau T, Larson D, Lee YK, Fink S, Smoley S, Paternoster S, Adeyinka A, Ketterling R, Van Dyke DL, Fonseca R, Kyle K: Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood 2005, 106:3553-3558
23. Dispenzieri A, Rajkumar SV, Gertz MA, Fonseca R, Lacy MQ, Bergsagel PL, Kyle RA, Greipp PR, Witzig TE, Reeder CB, Lust JA, Russell SJ, Hayman SR, Roy V, Kumar S, Zeldenrust SR, Dalton RJ, Stewart AK: Treatment of newly diagnosed multiple myeloma based on Mayo stratification of myeloma and risk-adapted therapy (mSMART): consensus statement. Mayo Clin Proc 2007, 82:323-341
24. Bacher U, Hochhaus A, Berger U, Hiddemann W, Hehlmann R, Haferlach T, Schoch C: Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha. Leukemia 2005, 19:460-463
25. Schoch C, Haferlach T, Kern W, Schnittger S, Berger U, Hehlmann R, Hiddemann W, Hochhaus A: Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate. Leukemia 2003, 17:461-463
26. O'Dwyer ME, Gatter KM, Loriaux M, Druker BJ, Olson SB, Magenis RE, Lawce H, Mauro MJ, Maziarz RT, Braziel RM: Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia 2003, 17:481-487
27. Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo LV, Cortes J: Myelo-dysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood 2006, 108:2811-2813
28. Giehl M, Fabarius A, Frank O, Hochhaus A, Hafner M, Hehlmann R, Seifarth W: Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability. Leukemia 2005, 19:1192-1197
29. Terre C, Eclache V, Rousselot P, Imbert M, Charrin C, Gervais C, Mozziconacci MJ, Maarek O, Mossafa H, Auger N, Dastugue N, Talmant P, van den AJ, Leonard C, Khac FN, Mugneret F, Viguie F, Lafage-Pochitaloff M, Bastie JN, Roux GL, Nicolini F, Maloisel F, Vey N, Laurent G, Recher C, Vigier M, Yacouben Y, Giraudier S, Vernant JP, Salles B, Roussi J, Castaigne S, Leymarie V, Flandrin G, Lessard M: Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 2004, 18:1340-1346
30. Fabarius A, Giehl M, Frank O, Duesberg P, Hochhaus A, Hehlmann R, Seifarth W: Induction of centrosome and chromosome aberrations by imatinib in vitro. Leukemia 2005, 19:1573-1578
31. Cook JR, Hartke M, Pettay J, Tubbs RR: Fluorescence in situ hybridization analysis of immunoglobulin heavy chain translocations in plasma cell myeloma using intact paraffin sections and simultaneous CD138 immunofluorescence. J Mol Diagn 2006, 8:459-465
32. Speel EJ, Hopman AH, Komminoth P: Tyramide signal amplification for DNA and mRNA in situ hybridization. Methods Mol Biol 2006, 326:33-60
33. Zhu L, Somlo G, Zhou B, Bedell V, Slovak ML, Liu X, Yen Y: Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma. Mol Cancer Ther 2005, 4:787-798
34. Evans PA, Pott C, Groenen PJ, Salles G, Davi F, Berger F, Garcia JF, van Krieken JH, Pals S, Kluin P, Schuuring E, Spaargaren M, Boone E, Gonzalez D, Martinez B, Villuendas R, Gameiro P, Diss TC, Mills K, Morgan GJ, Carter GI, Milner BJ, Pearson D, Hummel M, Jung W, Ott M, Canioni D, Beldjord K, Bastard C, Delfau-Larue MH, van Dongen JJ, Molina TJ, Cabeçadas J: Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of BIOMED-2 concerted action BHM4-CT98-3936. Leukemia 2007, 21:207-214
35. Talaulikar D, Gray JX, Shadbolt B, McNiven M, Dahlstrom J: A comparative study of the quality of DNA obtained from fresh frozen and formalin-fixed decalcified paraffin-embedded bone marrow trephine biopsies using two different methods. J Clin Path 2007, [Epub ahead of press]
36. Bagg A, Braziel RM, Arber DA, Bijwaard KE, Chu AY: Immunoglobulin heavy chain gene analysis in lymphomas: a multicenter study demonstrating the heterogeneity of performance of polymerase chain reaction assays. J Mol Diagn 2002, 4:81-89